JP2009149648A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009149648A5 JP2009149648A5 JP2008325914A JP2008325914A JP2009149648A5 JP 2009149648 A5 JP2009149648 A5 JP 2009149648A5 JP 2008325914 A JP2008325914 A JP 2008325914A JP 2008325914 A JP2008325914 A JP 2008325914A JP 2009149648 A5 JP2009149648 A5 JP 2009149648A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- aminomethyl
- carbonyl
- isobutanoyloxyethoxy
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- 239000013078 crystal Substances 0.000 claims 17
- TZDUHAJSIBHXDL-UHFFFAOYSA-N gabapentin enacarbil Chemical compound CC(C)C(=O)OC(C)OC(=O)NCC1(CC(O)=O)CCCCC1 TZDUHAJSIBHXDL-UHFFFAOYSA-N 0.000 claims 17
- 238000010521 absorption reaction Methods 0.000 claims 11
- 238000000634 powder X-ray diffraction Methods 0.000 claims 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- LJOODBDWMQKMFB-UHFFFAOYSA-N cyclohexylacetic acid Chemical compound OC(=O)CC1CCCCC1 LJOODBDWMQKMFB-UHFFFAOYSA-N 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010006002 Bone pain Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 206010061296 Motor dysfunction Diseases 0.000 claims 1
- 208000000112 Myalgia Diseases 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 238000000113 differential scanning calorimetry Methods 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000002844 melting Methods 0.000 claims 1
- 230000008018 melting Effects 0.000 claims 1
- 208000013465 muscle pain Diseases 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- -1 α-isobutanoyloxyethoxy Chemical group 0.000 claims 1
- 150000003953 γ-lactams Chemical class 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51128703P | 2003-10-14 | 2003-10-14 | |
| US60/511,287 | 2003-10-14 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006535673A Division JP4308263B2 (ja) | 2003-10-14 | 2004-10-14 | γ−アミノ酪酸アナログの結晶形 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009149648A JP2009149648A (ja) | 2009-07-09 |
| JP2009149648A5 true JP2009149648A5 (https=) | 2009-11-12 |
| JP4913796B2 JP4913796B2 (ja) | 2012-04-11 |
Family
ID=34465215
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006535673A Expired - Lifetime JP4308263B2 (ja) | 2003-10-14 | 2004-10-14 | γ−アミノ酪酸アナログの結晶形 |
| JP2008325914A Expired - Lifetime JP4913796B2 (ja) | 2003-10-14 | 2008-12-22 | γ−アミノ酪酸アナログの結晶形 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006535673A Expired - Lifetime JP4308263B2 (ja) | 2003-10-14 | 2004-10-14 | γ−アミノ酪酸アナログの結晶形 |
Country Status (22)
| Country | Link |
|---|---|
| US (10) | US8026279B2 (https=) |
| EP (1) | EP1677767B1 (https=) |
| JP (2) | JP4308263B2 (https=) |
| KR (1) | KR101096480B1 (https=) |
| CN (1) | CN1867322B (https=) |
| AT (1) | ATE516801T1 (https=) |
| AU (1) | AU2004282192B2 (https=) |
| BR (1) | BRPI0415288B8 (https=) |
| CA (1) | CA2541752C (https=) |
| DK (1) | DK1677767T3 (https=) |
| ES (1) | ES2368916T3 (https=) |
| IL (2) | IL174600A (https=) |
| MX (1) | MXPA06004088A (https=) |
| NO (1) | NO338275B1 (https=) |
| NZ (1) | NZ546381A (https=) |
| PL (1) | PL1677767T3 (https=) |
| PT (1) | PT1677767E (https=) |
| RU (1) | RU2412162C2 (https=) |
| SG (1) | SG147437A1 (https=) |
| SI (1) | SI1677767T1 (https=) |
| WO (1) | WO2005037784A2 (https=) |
| ZA (1) | ZA200602722B (https=) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US7186855B2 (en) | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US7025745B2 (en) * | 2002-10-07 | 2006-04-11 | Advanced Cardiovascular Systems, Inc. | Method of making a catheter balloon using a tapered mandrel |
| KR20060119971A (ko) * | 2003-09-11 | 2006-11-24 | 제노포트 인코포레이티드 | Ｇａｂａ 유사체의 전구약물을 이용한 요실금의 치료및/또는 예방 |
| AU2004274002B2 (en) * | 2003-09-17 | 2011-04-28 | Arbor Pharmaceuticals, Llc | Treating or preventing restless legs syndrome using prodrugs of GABA analogs |
| PT1677767E (pt) * | 2003-10-14 | 2011-10-13 | Xenoport Inc | Forma cristalina de análogo de ácido gama-aminobutírico |
| US20050209319A1 (en) * | 2004-03-18 | 2005-09-22 | Xenoport, Inc. | Treatment of local pain |
| CA2584338C (en) | 2004-11-04 | 2013-08-06 | Xenoport, Inc. | Gabapentin prodrug sustained release oral dosage forms |
| WO2007002013A2 (en) * | 2005-06-20 | 2007-01-04 | Xenoport, Inc. | Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use |
| WO2008073257A1 (en) * | 2006-12-08 | 2008-06-19 | Xenoport, Inc. | Use of prodrugs of gaba analogs for treating diseases |
| US20080206332A1 (en) * | 2007-01-11 | 2008-08-28 | Kidney David J | Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment |
| US20090118365A1 (en) * | 2007-11-06 | 2009-05-07 | Xenoport, Inc | Use of Prodrugs of GABA B Agonists for Treating Neuropathic and Musculoskeletal Pain |
| US20090318728A1 (en) * | 2008-06-24 | 2009-12-24 | Teva Pharmaceutical Industries Ltd. | Processes for preparing prodrugs of gabapentin and intermediates thereof |
| US20100004485A1 (en) * | 2008-07-02 | 2010-01-07 | Teva Pharmaceutical Industries Ltd. | Gabapentin enacarbil salts and processes for their preparation |
| WO2010017498A1 (en) | 2008-08-07 | 2010-02-11 | Xenoport, Inc. | Methods of synthesizing n-hydroxysuccinimidyl carbonates |
| WO2010017504A1 (en) * | 2008-08-07 | 2010-02-11 | Xenoport, Inc. | Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs |
| WO2010063002A2 (en) * | 2008-11-26 | 2010-06-03 | Teva Pharmaceutical Industries Ltd. | Processes for the preparation and purification of gabapentin enacarbil |
| WO2010075520A1 (en) * | 2008-12-23 | 2010-07-01 | Teva Pharmaceutical Industries Ltd. | Preparation of gabapentin enacarbil intermediate |
| EP2404588A4 (en) * | 2009-03-02 | 2012-08-01 | Astellas Pharma Inc | PACKAGING FOR SOLID PHARMACEUTICAL PREPARATION |
| NZ594648A (en) * | 2009-03-03 | 2013-12-20 | Xenoport Inc | Sustained release oral dosage forms of an r-baclofen prodrug |
| AU2010221167B2 (en) * | 2009-03-06 | 2014-04-03 | Xenoport, Inc. | Oral dosage forms having a high loading of a gabapentin prodrug |
| WO2011028234A1 (en) * | 2009-09-04 | 2011-03-10 | Xenoport, Inc. | Uses of acyloxyalkyl carbamate prodrugs of tranexamic acid |
| WO2011091164A1 (en) | 2010-01-22 | 2011-07-28 | Xenoport, Inc. | Oral dosage forms having a high loading of a tranexamic acid prodrug |
| US20110263701A1 (en) * | 2010-04-21 | 2011-10-27 | Sigal Blau | Gabapentin enacarbil compositions |
| WO2013008182A1 (en) * | 2011-07-10 | 2013-01-17 | Mahesh Kandula | Prodrugs of gaba analogs |
| US9303038B2 (en) | 2011-09-06 | 2016-04-05 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy and neurological diseases |
| WO2013168019A1 (en) * | 2012-05-07 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neuropathic pain |
| WO2013167985A1 (en) | 2012-05-07 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurological disorders |
| WO2013167990A1 (en) | 2012-05-07 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of depression |
| WO2013168021A1 (en) | 2012-05-07 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders |
| US9403826B2 (en) | 2012-05-08 | 2016-08-02 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory disorders |
| WO2013167991A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic disorders |
| WO2013168025A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of blood clotting disorders |
| WO2013168023A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of parkinson's disease |
| US9434704B2 (en) | 2012-05-08 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological degenerative disorders |
| WO2013168004A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of fibromyalgia pain |
| US9233161B2 (en) | 2012-05-10 | 2016-01-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological conditions |
| WO2013168033A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of neurologic diseases |
| WO2013167997A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic syndrome |
| WO2013168005A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of restless leg syndrome and fibromyalgia |
| WO2013168001A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
| WO2013168014A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of familial amyloid polyneuropathy |
| WO2013167999A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurologic diseases |
| US9394288B2 (en) | 2012-05-10 | 2016-07-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of asthma and allergy |
| US9403857B2 (en) | 2012-05-10 | 2016-08-02 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
| WO2013168012A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of respiratory disorders |
| US9273061B2 (en) | 2012-05-10 | 2016-03-01 | Cellix Bio Private Limited | Compositions and methods for the treatment of chronic pain |
| WO2013168000A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of severe pain |
| AU2013264820A1 (en) | 2012-05-23 | 2014-11-27 | Cellixbio Private Limited | Compositions and methods for treatment of mucositis |
| US9492409B2 (en) | 2012-05-23 | 2016-11-15 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
| EP2852569B1 (en) | 2012-05-23 | 2020-10-14 | Cellixbio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
| US9498461B2 (en) | 2012-05-23 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
| WO2013175344A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of periodontitis and rheumatoid arthritis |
| US9227974B2 (en) | 2012-05-23 | 2016-01-05 | Cellex Bio Private Limited | Compositions and methods for the treatment of respiratory disorders |
| US9108942B1 (en) | 2014-11-05 | 2015-08-18 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
| WO2014020480A2 (en) | 2012-08-03 | 2014-02-06 | Mahesh Kandula | Compositions and methods for the treatment migraine and neurologic diseases |
| WO2014037833A2 (en) | 2012-09-06 | 2014-03-13 | Mahesh Kandula | Compositions and methods for the treatment inflammation and lipid disorders |
| CN104364231A (zh) | 2012-09-08 | 2015-02-18 | 塞利克斯比奥私人有限公司 | 用于治疗炎症和脂质异常的组合物和方法 |
| US20150158809A9 (en) | 2013-02-26 | 2015-06-11 | Xenoport, Inc. | Method of making 1-(acyloxy)-alkyl carbamate compounds |
| US9333187B1 (en) | 2013-05-15 | 2016-05-10 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
| EP3004049B1 (en) | 2013-06-04 | 2018-09-05 | Cellixbio Private Limited | Compositions and methods for the treatment of diabetes and pre-diabetes |
| US9096537B1 (en) | 2014-12-31 | 2015-08-04 | Mahesh Kandula | Compositions and methods for the treatment of mucositis |
| EP3240779B1 (en) | 2014-09-26 | 2020-10-28 | Cellixbio Private Limited | Compositions and methods for the treatment of epilepsy and neurological disorders |
| JP6698643B2 (ja) | 2014-09-29 | 2020-05-27 | セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ | 多発性硬化症の治療のための組成物及び方法 |
| AU2014414316B2 (en) | 2014-10-27 | 2020-04-09 | Cellix Bio Private Limited | Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis |
| US10208014B2 (en) | 2014-11-05 | 2019-02-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological disorders |
| US9290486B1 (en) | 2014-11-05 | 2016-03-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy |
| US9175008B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Prodrugs of anti-platelet agents |
| US9284287B1 (en) | 2014-11-05 | 2016-03-15 | Cellix Bio Private Limited | Compositions and methods for the suppression of carbonic anhydrase activity |
| US9150557B1 (en) | 2014-11-05 | 2015-10-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of hyperglycemia |
| US9173877B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
| US9321716B1 (en) | 2014-11-05 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
| US9932294B2 (en) | 2014-12-01 | 2018-04-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
| US9206111B1 (en) | 2014-12-17 | 2015-12-08 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological diseases |
| CA2973178C (en) | 2015-01-06 | 2022-11-01 | Cellix Bio Private Limited | Bupivacaine derivatives and their use in the treatment of inflammation and pain |
| RU2739192C1 (ru) * | 2020-06-18 | 2020-12-21 | федеральное государственное бюджетное образовательное учреждение высшего образования «Омский государственный медицинский университет» Министерства здравоохранения Российской Федерации (ФГБОУ ВО ОмГМУ Минздрава России) | Способ лечения абстинентного синдрома, с целью превенции развития психоза, у лиц с зависимостью от синтетических агонистов рецепторов гамма-аминомасляной кислоты: бутиролактона, 1,4-бутандиола |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| DE2460891C2 (de) | 1974-12-21 | 1982-09-23 | Gödecke AG, 1000 Berlin | 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
| US4087544A (en) | 1974-12-21 | 1978-05-02 | Warner-Lambert Company | Treatment of cranial dysfunctions using novel cyclic amino acids |
| JPS62258337A (ja) | 1986-04-30 | 1987-11-10 | Kuraray Co Ltd | ４−ヒドロキシ−２，４，６−トリメチル−２，５−シクロヘキサジエン−１−オンの精製法 |
| DE3815221C2 (de) | 1988-05-04 | 1995-06-29 | Gradinger F Hermes Pharma | Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen |
| DE3928183A1 (de) | 1989-08-25 | 1991-02-28 | Goedecke Ag | Lactamfreie cyclische aminosaeuren |
| US5084169A (en) | 1989-09-19 | 1992-01-28 | The University Of Colorado Foundation, Inc. | Stationary magnetically stabilized fluidized bed for protein separation and purification |
| US5084479A (en) | 1990-01-02 | 1992-01-28 | Warner-Lambert Company | Novel methods for treating neurodegenerative diseases |
| AU9137091A (en) | 1990-11-27 | 1992-06-25 | Northwestern University | Gaba and l-glutamic acid analogs for antiseizure treatment |
| US6197819B1 (en) | 1990-11-27 | 2001-03-06 | Northwestern University | Gamma amino butyric acid analogs and optical isomers |
| US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
| JP3856816B2 (ja) | 1992-05-20 | 2006-12-13 | ノースウェスターン ユニヴァーシティ | 抗発作治療用のｇａｂａ及びｌ−グルタミン酸類縁体 |
| EP0888325B1 (en) | 1996-02-07 | 2002-05-29 | Warner-Lambert Company | Novel cyclic amino acids as pharmaceutical agents |
| HU224720B1 (en) | 1996-03-14 | 2006-01-30 | Warner Lambert Co | Novel substituted cyclic amino acid derivatives use as pharmaceutical agents |
| WO1997033859A1 (en) | 1996-03-14 | 1997-09-18 | Warner-Lambert Company | Novel bridged cyclic amino acids as pharmaceutical agents |
| IL126999A (en) | 1996-07-24 | 2002-03-10 | Warner Lambert Co | Pharmaceutical preparations containing isobutylgaba and its history for use in the treatment of pain |
| SE9603408D0 (sv) * | 1996-09-18 | 1996-09-18 | Astra Ab | Medical use |
| ATE361909T1 (de) | 1996-10-23 | 2007-06-15 | Warner Lambert Co | Substituierte gamma-aminobuttersäurederivate als arzneimittel |
| WO1999008670A1 (en) | 1997-08-20 | 1999-02-25 | Guglietta, Antonio | Gaba analogs to prevent and treat gastrointestinal damage |
| ATE323067T1 (de) | 1997-10-27 | 2006-04-15 | Warner Lambert Co | Zyklische aminosäuren und deren derivate als arzneimittel |
| CA2304967C (en) | 1997-12-16 | 2005-06-14 | Warner-Lambert Company | 4(3)substituted-4(3)-aminomethyl-(thio)pyran or -piperidine derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders |
| CN1131855C (zh) | 1997-12-16 | 2003-12-24 | 沃尼尔·朗伯公司 | 1－取代－1－氨基甲基－环烷衍生物(=加巴喷丁类似物)、其制备及其在治疗神经病方面的用途 |
| SI1045839T1 (en) | 1997-12-16 | 2004-06-30 | Warner-Lambert Company Llc | Novel amines as pharmaceutical agents |
| US6605610B1 (en) | 1997-12-31 | 2003-08-12 | Pfizer Inc | Aryl fused azapolycyclic compounds |
| CA2309354A1 (en) | 1998-01-23 | 1999-07-29 | Leslie Magnus-Miller | Gabapentin and its derivatives for the treatment of muscular and skeletal pain |
| WO1999061424A1 (en) | 1998-05-26 | 1999-12-02 | Warner-Lambert Company | Conformationally constrained amino acid compounds having affinity for the alpha2delta subunit of a calcium channel |
| AUPP396998A0 (en) | 1998-06-09 | 1998-07-02 | University Of Melbourne, The | A method for increasing the permeability of wood |
| CA2344407C (en) | 1998-10-16 | 2007-01-09 | Warner-Lambert Company | Method for the treatment of mania and bipolar disorder |
| US6627771B1 (en) | 1998-11-25 | 2003-09-30 | Pfizer Inc | Gamma amino butyric and acid analogs |
| EP1031350A1 (en) | 1999-02-23 | 2000-08-30 | Warner-Lambert Company | Use of a gabapentin-analog for the manufacture of a medicament for preventing and treating visceral pain |
| EP1977745B1 (en) | 1999-04-08 | 2010-04-07 | Warner-Lambert Company LLC | Treatment of incontinence |
| US6992109B1 (en) | 1999-04-08 | 2006-01-31 | Segal Catherine A | Method for the treatment of incontinence |
| AU767119B2 (en) | 1999-07-22 | 2003-10-30 | University Of Rochester | Method of treating symptoms of hormonal variation, including hot flashes |
| GB2362646A (en) | 2000-05-26 | 2001-11-28 | Warner Lambert Co | Cyclic amino acid derivatives useful as pharmaceutical agents |
| IL152770A0 (en) | 2000-06-26 | 2003-06-24 | Warner Lambert Co | Gabapentin analogues for sleep disorders |
| GB2365425A (en) | 2000-08-01 | 2002-02-20 | Parke Davis & Co Ltd | Alkyl amino acid derivatives useful as pharmaceutical agents |
| WO2002028881A1 (en) | 2000-10-06 | 2002-04-11 | Xenoport, Inc. | Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration |
| EP1361847A2 (en) | 2000-10-06 | 2003-11-19 | Xenoport, Inc. | Bile-acid conjugates for providing sustained systemic concentrations of drugs |
| WO2002028411A1 (en) | 2000-10-06 | 2002-04-11 | Xenoport, Inc. | Compounds for sustained release of orally delivered drugs |
| GB2368579A (en) | 2000-10-31 | 2002-05-08 | Parke Davis & Co Ltd | Azole pharmaceutical agents |
| AU2002239257A1 (en) | 2000-11-17 | 2002-06-03 | Xenoport, Inc. | Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
| JP2002346303A (ja) | 2001-05-28 | 2002-12-03 | Mitsubishi Chemicals Corp | 晶析方法 |
| JP2002355501A (ja) | 2001-05-30 | 2002-12-10 | Sumitomo Chem Co Ltd | 滴下晶析方法 |
| ATE540678T1 (de) | 2001-06-11 | 2012-01-15 | Xenoport Inc | Prodrugs aus gaba-analoga, zusammensetzungen und ihre verwendungen |
| US7186855B2 (en) | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US7232924B2 (en) * | 2001-06-11 | 2007-06-19 | Xenoport, Inc. | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs |
| US6818787B2 (en) | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| WO2003077902A1 (en) | 2002-02-19 | 2003-09-25 | Xenoport, Inc. | Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof |
| JP2006522146A (ja) | 2003-03-31 | 2006-09-28 | ゼノポート，インコーポレイティド | Ｇａｂａ類似体のプロドラッグを使用するのぼせの治療または予防 |
| US6816787B2 (en) | 2003-03-31 | 2004-11-09 | Schlumberger Technology Corporation | Generating and displaying a virtual core and a virtual plug associated with a selected piece of the virtual core |
| WO2005010011A2 (en) | 2003-07-15 | 2005-02-03 | Xenoport, Inc. | Methods of synthesis of acyloxyalkyl compounds |
| KR20060119971A (ko) | 2003-09-11 | 2006-11-24 | 제노포트 인코포레이티드 | Ｇａｂａ 유사체의 전구약물을 이용한 요실금의 치료및/또는 예방 |
| AU2004274002B2 (en) | 2003-09-17 | 2011-04-28 | Arbor Pharmaceuticals, Llc | Treating or preventing restless legs syndrome using prodrugs of GABA analogs |
| PT1677767E (pt) | 2003-10-14 | 2011-10-13 | Xenoport Inc | Forma cristalina de análogo de ácido gama-aminobutírico |
| EP2371815A1 (en) | 2003-12-30 | 2011-10-05 | XenoPort, Inc. | Sythesis of acyloxyalkyl carbamate prodrugs and intermediates thereof |
| US20050209319A1 (en) | 2004-03-18 | 2005-09-22 | Xenoport, Inc. | Treatment of local pain |
| CA2584338C (en) * | 2004-11-04 | 2013-08-06 | Xenoport, Inc. | Gabapentin prodrug sustained release oral dosage forms |
| US20080188562A1 (en) | 2006-11-14 | 2008-08-07 | Noa Zerangue | Treating tinnitus using prodrugs of gabapentin and pregabalin |
| WO2008073257A1 (en) | 2006-12-08 | 2008-06-19 | Xenoport, Inc. | Use of prodrugs of gaba analogs for treating diseases |
-
2004
- 2004-10-14 PT PT04795177T patent/PT1677767E/pt unknown
- 2004-10-14 AU AU2004282192A patent/AU2004282192B2/en not_active Ceased
- 2004-10-14 CN CN200480030148.4A patent/CN1867322B/zh not_active Expired - Fee Related
- 2004-10-14 US US10/966,507 patent/US8026279B2/en active Active
- 2004-10-14 JP JP2006535673A patent/JP4308263B2/ja not_active Expired - Lifetime
- 2004-10-14 EP EP04795177A patent/EP1677767B1/en not_active Expired - Lifetime
- 2004-10-14 AT AT04795177T patent/ATE516801T1/de active
- 2004-10-14 PL PL04795177T patent/PL1677767T3/pl unknown
- 2004-10-14 SI SI200431753T patent/SI1677767T1/sl unknown
- 2004-10-14 CA CA2541752A patent/CA2541752C/en not_active Expired - Lifetime
- 2004-10-14 RU RU2006116470/04A patent/RU2412162C2/ru not_active IP Right Cessation
- 2004-10-14 MX MXPA06004088A patent/MXPA06004088A/es active IP Right Grant
- 2004-10-14 WO PCT/US2004/033979 patent/WO2005037784A2/en not_active Ceased
- 2004-10-14 NZ NZ546381A patent/NZ546381A/en not_active IP Right Cessation
- 2004-10-14 DK DK04795177.7T patent/DK1677767T3/da active
- 2004-10-14 SG SG200807649-9A patent/SG147437A1/en unknown
- 2004-10-14 KR KR1020067007286A patent/KR101096480B1/ko not_active Expired - Lifetime
- 2004-10-14 ES ES04795177T patent/ES2368916T3/es not_active Expired - Lifetime
- 2004-10-14 BR BRPI0415288A patent/BRPI0415288B8/pt not_active IP Right Cessation
-
2006
- 2006-03-27 IL IL174600A patent/IL174600A/en active IP Right Grant
- 2006-04-03 ZA ZA2006/02722A patent/ZA200602722B/en unknown
- 2006-05-11 NO NO20062112A patent/NO338275B1/no not_active IP Right Cessation
-
2008
- 2008-12-22 JP JP2008325914A patent/JP4913796B2/ja not_active Expired - Lifetime
-
2009
- 2009-08-26 US US12/548,200 patent/US20100056632A1/en not_active Abandoned
- 2009-12-08 IL IL202603A patent/IL202603A/en active IP Right Grant
-
2010
- 2010-10-04 US US12/897,567 patent/US20110021628A1/en not_active Abandoned
-
2011
- 2011-06-20 US US13/164,620 patent/US8686034B2/en not_active Expired - Lifetime
-
2014
- 2014-03-12 US US14/206,893 patent/US9150503B2/en not_active Expired - Lifetime
-
2015
- 2015-08-20 US US14/831,688 patent/US20150353483A1/en not_active Abandoned
-
2017
- 2017-03-13 US US15/457,191 patent/US20170183296A1/en not_active Abandoned
-
2019
- 2019-01-29 US US16/261,191 patent/US20190152900A1/en not_active Abandoned
-
2020
- 2020-01-13 US US16/741,113 patent/US20200283376A1/en not_active Abandoned
-
2021
- 2021-09-20 US US17/479,382 patent/US20220251031A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009149648A5 (https=) | ||
| JP2010514806A5 (https=) | ||
| ES2606752T3 (es) | Método para la preparación de (2S,3R)-N-(2-((3-piridinil)metil)-1-azabiciclo[2.2.2]oct-3-il)benzofuran-2- carboxamida | |
| AU2017209250B2 (en) | Angiotensin II receptor antagonist metabolite and NEP inhibitor composite, and preparation method thereof | |
| US20240165097A1 (en) | Pharmaceutical composition for the treatment of alzheimer's disease or dementia | |
| ES2503465T3 (es) | Preparación y aplicaciones terapéuticas de (2S,3R)-N-2-((3-piridinil)metil)-1-azabiciclo[2.2.2]oct-3-il)-3,5-di-fluorobenzamida | |
| JP2011522827A5 (https=) | ||
| JP2011516417A5 (https=) | ||
| JP2009536176A5 (https=) | ||
| TW201204724A (en) | Cis-tetrahydro-spiro(cyclohexane-1,1'-pyrido[3,4-b]indole)-4-amine derivatives | |
| EA201000384A1 (ru) | Новая полиморфная форма ротиготина и способ её получения | |
| RU2007147427A (ru) | Кристаллические и другие формы солей, образованных из молочной кислоты и 4-амино-5-фтор-3-[6-(4-метилпиперазин-1-ил)-1н-бензимидазол-2-ил]-1н-хинолин-2-она | |
| TW200808726A (en) | Novel polymorph forms of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine | |
| CN103113405B (zh) | 苯磷硫胺多晶型体、制备方法及其应用 | |
| CN102351857A (zh) | 盐酸托烷司琼化合物 | |
| JP2021503480A5 (https=) | ||
| CN118593482A (zh) | 非外消旋混合物及其用途 | |
| JP2020536893A5 (https=) | ||
| JP2022511869A (ja) | ムスカリンｍ１および／またはｍ４受容体アゴニストとしての二環式アザ化合物 | |
| JP2025521564A (ja) | Ｒ－ｍｄｍａ結晶形態 | |
| JP2012533559A5 (https=) | ||
| JP2024009114A (ja) | ミネラルコルチコイド受容体拮抗剤としての化合物の結晶形及びその調製方法 | |
| CN103864760A (zh) | 一种盐酸法舒地尔化合物 | |
| JP2009541455A5 (https=) | ||
| TW200845977A (en) | Sub-type selective azabicycloalkane derivatives |